Abstracts Archive - Page 336 of 2425 - ACR Meeting Abstracts

Abstract Number: 1939 • ACR Convergence 2023
Sinonasal Sarcoidosis Associated with Chronic Pulmonary Disease, Deficiency Anemias, and Obesity
Emily Kokush, Mary Salim, Eugenio Capitle, Reena Khianey and Evelyne Kalyoussef, Rutgers New Jersey Medical School, Newark, NJ
Background/Purpose: Sarcoidosis is a systemic granulomatous inflammatory disease that can involve multiple organ systems. Rarely, sarcoidosis can involve the upper respiratory tract including the sinonasal…
Abstract Number: 1345 • ACR Convergence 2023
Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy
Michelle Ann Caesar, Diana Johnson, Kenneth Lyons Jones and Christina Chambers, University of California San Diego, La Jolla, CA
Background/Purpose: Abatacept is approved for the treatment of moderate to severe rheumatoid arthritis (RA) and psoriatic arthritis. However, there are limited data on the safety…
Abstract Number: 1977 • ACR Convergence 2023
Combined Datasets for CNTX-4975 Osteoarthritis Knee Pain (OAKP) Phase 3 Trials (OAKP 301 and 304) to Assess Overall Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (MSOAKP)
James Connolly, James N Campbell, Randall Stevens and Colleen Newman, Centrexion Therapeutics Corporation, Boston, MA
Background/Purpose: 30+ million US adults have OAKP, (13% women / 10% men). After years of using NSAIDs, analgesics, surgery and IAI, many patients remain with…
Abstract Number: 1937 • ACR Convergence 2023
Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis
Frank Cai¹, Anisha Paulson¹, Amy Wozniak², Emily Gilbert² and Rochella Ostrowski², ¹Loyola University Medical Center, Oak Park, IL, ²Loyola University Medical Center, Maywood, IL
Background/Purpose: There is currently a lack of a consensus standardized guideline for the treatment of cardiac sarcoidosis (CS) because of its rarity, heterogeneity of disease…
Abstract Number: 1901 • ACR Convergence 2023
Which ASDAS-ESR Cut-offs for Disease Activity Correspond to ASDAS-CRP Cut-offs in Axial Spondyloarthritis? – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Lykke Ørnbjerg¹, Brigitte Michelsen², Tore Kvien³, Daniela Di Giuseppe⁴, Johan Karlsson Wallman⁵, Jakub Zavada⁶, Sella Provan⁷, Ana Maria Rodrigues⁸, Maria Jose Santos⁹, Ziga Rotar¹⁰, Dan Nordstrom¹¹, Anna-Mari Hokkanen¹², Gary Macfarlane¹³, Gareth T. Jones¹³, Irene van der Horst-Bruinsma¹⁴, Pasoon Hellamand¹⁵, Mikkel Østergaard¹⁶ and Merete Hetland¹, ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ³Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Lund University and Skåne University Hospital, Lund, Sweden, ⁶Institute of Rheumatology; Charles University, Prague, Czech Republic, ⁷Diakonhjemmet Hospital, Oslo, Norway, ⁸Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ⁹Hospital Garcia de Orta, Almada, Lisboa, Portugal, ¹⁰University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Helsinki University and Helsinki University Hospital, Helsinki, Finland, ¹³Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ¹⁴Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands, ¹⁵Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: When assessing disease activity in patients with axial spondyloarthritis (axSpA), the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) is recommended over ASDAS…
Abstract Number: 1929 • ACR Convergence 2023
Anakinra Treatment in Idiopathic Recurrent Pericarditis: A Single-center Experience
Zeynep Toker Dincer¹, Sejla Karup², Erkin Yilmaz¹, Osman Corbali¹ and Serdal Ugurlu¹, ¹Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Idiopathic recurrent pericarditis (IRP) is defined by recurring episodes of pericardial inflammation without a known cause. This study investigates the safety and efficacy of…
Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Marion THOMAS¹, Maeva MASSON², Raphaele Seror³, Samuel Bitoun⁴, Henry DUPUY⁵, Lazato ESTIBALIZ⁵, Christophe Richez⁶, Yannick ALLANORE⁷ and Jerome AVOUAC⁸, ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²CHU Toulouse, Toulouse, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
Abstract Number: 1980 • ACR Convergence 2023
Movement Evoked Pain as an Outcome Measure in Patients with Knee Osteoarthritis
Leila Bagherzadeh¹, Schnitzer Thomas², Santiago Espinosa-Salas¹ and Joana Barroso³, ¹Northwestern Physical Medicine and Rehabilitation Department, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Anesthesiology; Feinberg School of Medicine, Chicago, IL
Background/Purpose: Pain, being one of the most crucial symptoms associated with knee OA, serves as a significant outcome measure for the increasing number of studies…
Abstract Number: 1983 • ACR Convergence 2023
Heated Mittens for Patients with Hand Osteoarthritis: A Randomized Trial
Cecilie Bartholdy¹, Anna Døssing², Zara Stisen¹, Sabrina Mai Nielsen³, Henning Bliddal¹, Robin Christensen⁴, Marius Henriksen¹ and Karen Ellegaard¹, ¹The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ²The Parker Institutte, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ³The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark
Background/Purpose: Hand Osteoarthritis (OA) is common and causes pain and disability. Heat is anecdotally known to moderate symptoms and is conditionally recommended as a treatment…
Abstract Number: 1989 • ACR Convergence 2023
Shared Variation Among Cartilage Thickness Change Maps and Baseline Clinical Features at the Initiation of Structural Knee Osteoarthritis
Thomas Keefe¹, Marc Niethammer¹, Boqi Chen¹, Zhengyang Shen¹, Daniel Nissman¹, Mary Catherine Minnig², Yvonne Golightly³, J.S. Marron¹ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Durham, NC, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To identify features of cartilage thickness change and baseline clinical indicators associated with the transition from normal to mildly reduced joint space as an…
Abstract Number: 1759 • ACR Convergence 2023
Runx1 Is a Key Transcription Factor That Drives Synovial Fibroblast Pathogenicity in Rheumatoid Arthritis
Christopher Mahony¹, Samuel Kemble², Paulynn Chin¹, Cesar Prada³, Annie Hackland¹, Patricia Reis-Nisa¹, Lucy-Jayne Marsh¹, Peter Keane¹, Constanze Bonifer¹, Christopher Buckley⁴, Stevephen Sansom⁵, Mark Coles⁴ and Adam Croft¹, ¹University of Birmingham, Birmingham, United Kingdom, ²University Birmingham, Rugeley, United Kingdom, ³The Kennedy Institute, Oxford, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵Kennedy Institute of Rheumatology, Oxford, United Kingdom
Background/Purpose: Fibroblasts are key effector cells in rheumatoid arthritis (RA) underpinning joint inflammation and damage. Synovial tissue fibroblasts are heterogenous and acquire pathogenic cell states…
Abstract Number: 1925 • ACR Convergence 2023
Importance of the Patient Pain Experience in Disease Activity Assessment in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Study
Aleksander Lenert¹, Robyn Domsic², Karmela Kim Chan³, Melissa Oliver⁴, Jisna Paul⁵, Courtney Kremer⁶, Emma Leisinger¹, Helena Abodeely¹, Sandy Hong⁶, Arundathi Jayatilleke⁷, Petar Lenert⁸, T. Shawn Sato¹, Yongdong (Dan) Zhao⁹, Jonathan Templin¹, Mary Vaughan-Sarrazin¹, Daniel Solomon¹⁰ and Polly Ferguson¹¹, ¹University of Iowa, Iowa City, IA, ²University of Pittsburgh, Pittsburgh, PA, ³Hospital For Special Surgery, New York, NY, ⁴Indiana University, Indianapolis, IN, ⁵Ohio State University Hospital, Columbus, OH, ⁶University of Iowa Stead Family Children's Hospital, Iowa City, IA, ⁷Temple University, Philadelphia, PA, ⁸University of Iowa Hospitals and Clinics, Iowa City, IA, ⁹University of Washington, Seattle, WA, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Musculoskeletal pain is a key symptom experienced by patients with SAPHO and chronic nonbacterial osteomyelitis (SAPHO-CNO), yet its relation to disease activity assessment remains…
Abstract Number: 1907 • ACR Convergence 2023
Selection of a Candidate Instrument to Assess Flare in Osteoarthritis with Content Matching with Endorsed Domains
Fabiana Queiroga¹, Marita Cross², Lara Maxwell³, Leigh Callahan⁴, sam michel Cembalo⁵, Thomas Buttel², Cindy Copenhaver⁶, Jonathan Epstein⁷, david Hunter⁸, Lauren King⁹, Lyn March² and Francis Guillemin¹⁰, ¹Université de Lorraine, Antibes, France, ²University of Sydney, Sydney, Australia, ³OMERACT, Ottawa, ON, Canada, ⁴The University of North Carolina, Chapel Hill, NC, ⁵OMERACT, Nancy, France, ⁶OMERACT, Chapel Hill, NC, ⁷Université de Lorraine, Nancy, France, ⁸Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, ⁹Clinical Associate, Division of Rheumatology, St. Michael’s Hospital, Toronto, ON, Canada, ¹⁰Université de Lorraine, EA 4360 Apemac, Nancy, France
Background/Purpose: The Outcome Measures in Rheumatology group (OMERACT) developed methodological steps to select instrument(s) to assess content appropriateness of outcomes, as well as tools to…
Abstract Number: 1423 • ACR Convergence 2023
Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial
Laura Coates¹, Catherine Bakewell², Majed Khraishi³, Shirley Chen⁴, Tianming Gao⁴, Arathi Setty⁴, Heather Jones⁵, Sandra Ciecinski⁴ and Eduardo Mysler⁶, ¹University of Oxford, Oxford, United Kingdom, ²Intermountain Healthcare Medical Group, Salt Lake City, UT, ³Memorial University of Newfoundland, St. John's, NL, Canada, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Mettawa, IL, ⁶Organización Medica de Investigación, Buenos Aires, Argentina
Background/Purpose: Enthesitis and dactylitis are associated with reduced quality of life and greater impairment in daily activities. In the SELECT-PsA 2 phase 3 trial, the…
Abstract Number: 1975 • ACR Convergence 2023
Do You Believe in Exercise for Osteoarthritis? Exploring Differences in Participant Characteristics with Treatment Beliefs in Exercise for Knee Osteoarthritis
Sydney Liles¹, Jason Jakiela², Thomas Bye², Jennifer Copson² and Daniel White², ¹University of Delaware, Elkton, MD, ²University of Delaware, Newark, DE
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of disability and functional limitation in older adults. Treatments for knee OA focus on symptom management, with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].